- Home
- ONVO
as 04-25-2025 4:00pm EST
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 347.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.56 - $21.96 | Next Earning Date: | 05-30-2025 |
| Revenue: | $122,000 | Revenue Growth: | -49.59% |
| Revenue Growth (this year): | 59.08% | Revenue Growth (next year): | 18.24% |
Latest Organovo Holdings Inc. News
ONVO Breaking Stock News: Dive into ONVO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
GlobeNewswire
3 days ago
VivoSim to Carry Forward Organovo 3D Bioprinting
GlobeNewswire
24 days ago
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
GlobeNewswire
a month ago
Organovo Provides Business Update
GlobeNewswire
a month ago
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
MT Newswires
a month ago
Top Midday Decliners
GlobeNewswire
a month ago
Organovo Announces Reverse Stock Split
GlobeNewswire
2 months ago
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Compare ONVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ONVO Organovo Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.